INIS
clinical trials
100%
vaccines
100%
influenza
100%
doses
88%
antibodies
44%
symptoms
33%
inhibition
33%
hemagglutination
33%
antigens
22%
mixing
22%
geometry
22%
administration
11%
humans
11%
data
11%
design
11%
safety
11%
mortality
11%
morbidity
11%
viruses
11%
values
11%
peaks
11%
receipts
11%
china
11%
hemagglutinins
11%
aged adults
11%
Keyphrases
MF59 Adjuvant
100%
H7N9 Vaccine
100%
H7N9 Influenza Virus
100%
Post-vaccination Symptoms
33%
Antigen Dose
33%
Neutralizing Antibody Assay
16%
Seasonal Influenza Vaccination
16%
Nominal Dose
16%
Age of Vaccination
16%
H7N9
16%
Medicine and Dentistry
Mifamurtide
100%
Influenza A (H7N9)
100%
Avian Influenza
100%
Influenza A Virus (H7N9)
62%
Seasonal Influenza
12%
Hemagglutination Inhibiting Antibody
12%
Pharmacology, Toxicology and Pharmaceutical Science
MF59
100%
Influenza A (H7N9)
100%
Influenza A Virus (H7N9)
62%
Immunology and Microbiology
MF59
100%
Influenza A Virus (H7N9)
100%